Picture of Angle logo

AGL Angle News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - Angle PLC - Appointments: Interim CEO and senior board advisor

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP5686Da&default-theme=true

RNS Number : 5686D  Angle PLC  16 October 2025

16 October 2025

 

ANGLE plc ("the Company")

 

APPOINTMENT OF INTERIM CEO AND SENIOR BOARD ADVISOR

 

ANGLE plc (to be renamed CelLBxHealth plc) (AIM:ANGL OTCQX:ANPCY), a
world-leading circulating tumour cell (CTC) intelligence company with tests
for use in research, drug development and clinical oncology, announces that
it has strengthened its management team through two senior hires.

 

Peter Collins has been appointed as interim Chief Executive Officer of the
Company and Klaas de Boer joins as a senior advisor to the Board.

 

Peter Collins brings over 25 years of experience in oncology drug and
diagnostics development, having held senior executive positions across both
private and publicly listed companies. He joins the Company following a series
of successful leadership roles at leading oncology diagnostics organisations,
including Chief Executive Officer at SAGA Diagnostics, Chief Business Officer
at Inivata, Vice President, Biopharma Business Development at Guardant Health,
and Head of Diagnostics at GSK.

 

Throughout his career, Peter has demonstrated a consistent record of building
high-performing teams and driving commercial growth across international
healthcare markets.  As interim CEO, he joins the Company in a non-board
capacity.

 

Klaas de Boer holds numerous board positions with both public and private
international companies including Xeros plc, SmartKem, Inc. and General
Fusion, Inc. He began his career with McKinsey & Company before
transitioning to venture capital more than 25 years ago; initially with Baan
Investment, and later as Managing Partner with Entrepreneurs Fund. His
experience in the finance and technology sectors will be invaluable as the
Company goes through a restructure and funding in Q4.

 

Dr Jan Groen, Executive Chairman commented:

 

"Peter is an exceptional leader with a proven track record of commercial
excellence, disciplined execution, and innovation. The Board is delighted that
he has agreed to serve as interim CEO while we continue the process to make a
permanent appointment. We are also delighted to have Klaas assisting the Board
and management team during the coming period."

 

 

 

 For further information:

 

 ANGLE plc                                       +44 (0) 1483 343434

 Dr Jan Groen, Executive Chairman                 investors@angleplc.com
 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 FTI Consulting

 Simon Conway, Ciara Martin, Sam Purewal         +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                        +1 (212) 850 5624

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc (to be re-named CelLBxHealth plc)

ANGLE plc is a global precision CTC intelligence company specialising in
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology. Its patent-protected Parsortix® platform
harvests CTCs from blood and enables comprehensive downstream analysis -
including whole-cell imaging, proteomic profiling and full genomic workflows -
supporting research, drug development and clinical oncology.

 

Commercial activities centre on (i) biopharma clinical services, (ii)
partnerships, (iii) development of laboratory-developed tests (LDTs), and (iv)
Research Use Only validation of existing commercial proteomic and genomic
assays. The product portfolio comprises the Parsortix® platform with
associated consumables and assays. Biopharma services are delivered from
ANGLE's GCLP-compliant UK laboratory, providing bespoke LDT development,
clinical-trial testing and custom services.

 

For more information, visit www.angleplc.com (http://www.angleplc.com) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPESFSXSFFA



            Copyright 2019 Regulatory News Service, all rights reserved

Recent news on Angle

See all news